Published in Clinical Trials Week, November 14th, 2005
The European Infliximab for Psoriasis Efficacy and Safety Study was a placebo-controlled trial on 378 patients with moderate-to-severe psoriasis, to test the efficacy and safety of the drug. The findings, published in the October 15, 2005 issue of The Lancet, show that 80% of patients achieved at least a 75% improvement in symptoms after 10 weeks' treatment with the drug, as opposed to just 3% of those receiving a placebo.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.